Andrea Ciaranello MD MPH, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Infectious Disease Transmission, Vertical | 19 | 2020 | 1320 | 3.580 |
Why?
|
HIV Infections | 58 | 2021 | 16718 | 2.920 |
Why?
|
Anti-HIV Agents | 25 | 2020 | 4256 | 1.860 |
Why?
|
Pregnancy Complications, Infectious | 13 | 2020 | 2026 | 1.540 |
Why?
|
Anti-Retroviral Agents | 10 | 2020 | 1715 | 1.520 |
Why?
|
Cost-Benefit Analysis | 20 | 2021 | 5391 | 1.210 |
Why?
|
Early Diagnosis | 9 | 2020 | 1184 | 1.150 |
Why?
|
Breast Feeding | 9 | 2020 | 1338 | 0.910 |
Why?
|
CD4 Lymphocyte Count | 10 | 2021 | 2559 | 0.820 |
Why?
|
World Health Organization | 9 | 2020 | 1318 | 0.800 |
Why?
|
South Africa | 13 | 2020 | 1731 | 0.740 |
Why?
|
Zimbabwe | 6 | 2020 | 129 | 0.700 |
Why?
|
Models, Economic | 2 | 2020 | 713 | 0.690 |
Why?
|
Point-of-Care Systems | 2 | 2019 | 1177 | 0.640 |
Why?
|
Health Care Costs | 10 | 2020 | 3209 | 0.630 |
Why?
|
Infant | 30 | 2020 | 35136 | 0.620 |
Why?
|
Ritonavir | 4 | 2016 | 322 | 0.600 |
Why?
|
Infant, Small for Gestational Age | 1 | 2019 | 440 | 0.580 |
Why?
|
Nevirapine | 3 | 2015 | 267 | 0.570 |
Why?
|
Models, Theoretical | 7 | 2019 | 3589 | 0.530 |
Why?
|
Life Expectancy | 7 | 2019 | 1184 | 0.510 |
Why?
|
Infant, Newborn | 21 | 2020 | 25625 | 0.500 |
Why?
|
Health Resources | 4 | 2020 | 911 | 0.500 |
Why?
|
Antiretroviral Therapy, Highly Active | 5 | 2019 | 1873 | 0.480 |
Why?
|
HIV | 3 | 2018 | 1604 | 0.480 |
Why?
|
Clinical Laboratory Techniques | 4 | 2020 | 738 | 0.470 |
Why?
|
Drug Dosage Calculations | 1 | 2014 | 114 | 0.470 |
Why?
|
Infant Mortality | 1 | 2018 | 754 | 0.440 |
Why?
|
Diagnostic Tests, Routine | 1 | 2019 | 783 | 0.440 |
Why?
|
Pregnancy | 24 | 2020 | 29144 | 0.430 |
Why?
|
Epidemics | 1 | 2018 | 523 | 0.420 |
Why?
|
Computer Simulation | 5 | 2019 | 6196 | 0.390 |
Why?
|
Disease Transmission, Infectious | 1 | 2015 | 547 | 0.350 |
Why?
|
Acquired Immunodeficiency Syndrome | 6 | 2020 | 2232 | 0.350 |
Why?
|
Heterocyclic Compounds, 3-Ring | 3 | 2019 | 215 | 0.330 |
Why?
|
Infant Care | 2 | 2020 | 183 | 0.330 |
Why?
|
Pyrimidinones | 1 | 2011 | 371 | 0.320 |
Why?
|
Mass Screening | 3 | 2020 | 5255 | 0.310 |
Why?
|
Premature Birth | 1 | 2019 | 1721 | 0.300 |
Why?
|
Halfway Houses | 1 | 2006 | 11 | 0.290 |
Why?
|
Kaposi Varicelliform Eruption | 1 | 2006 | 47 | 0.280 |
Why?
|
Communicable Disease Control | 2 | 2020 | 857 | 0.280 |
Why?
|
Costs and Cost Analysis | 3 | 2020 | 1681 | 0.280 |
Why?
|
Drug Costs | 1 | 2014 | 1105 | 0.280 |
Why?
|
Young Adult | 20 | 2021 | 56430 | 0.280 |
Why?
|
Africa | 4 | 2020 | 673 | 0.270 |
Why?
|
Quality-Adjusted Life Years | 4 | 2021 | 1683 | 0.260 |
Why?
|
Female | 51 | 2020 | 380194 | 0.250 |
Why?
|
Viral Load | 7 | 2020 | 3299 | 0.240 |
Why?
|
Humans | 70 | 2021 | 744343 | 0.240 |
Why?
|
Perinatal Care | 2 | 2018 | 227 | 0.230 |
Why?
|
Adolescent | 22 | 2021 | 85781 | 0.220 |
Why?
|
HIV-1 | 7 | 2020 | 6939 | 0.220 |
Why?
|
Body Weight | 1 | 2014 | 4669 | 0.220 |
Why?
|
Child, Preschool | 14 | 2020 | 41006 | 0.220 |
Why?
|
Practice Guidelines as Topic | 4 | 2020 | 7279 | 0.220 |
Why?
|
Adult | 32 | 2021 | 214055 | 0.210 |
Why?
|
Guidelines as Topic | 3 | 2014 | 1405 | 0.210 |
Why?
|
Child | 19 | 2020 | 77709 | 0.210 |
Why?
|
Exanthema | 1 | 2006 | 501 | 0.200 |
Why?
|
Tuberculosis | 1 | 2014 | 1912 | 0.200 |
Why?
|
Zidovudine | 2 | 2015 | 620 | 0.190 |
Why?
|
Neural Tube Defects | 2 | 2019 | 256 | 0.180 |
Why?
|
Health Services Accessibility | 2 | 2009 | 5137 | 0.180 |
Why?
|
Time and Motion Studies | 1 | 2020 | 149 | 0.180 |
Why?
|
Patient Isolation | 1 | 2020 | 100 | 0.180 |
Why?
|
Audiovisual Aids | 1 | 2020 | 92 | 0.170 |
Why?
|
Africa, Eastern | 2 | 2020 | 71 | 0.170 |
Why?
|
Postpartum Period | 3 | 2020 | 1086 | 0.170 |
Why?
|
Male | 33 | 2021 | 350118 | 0.160 |
Why?
|
Nurse-Patient Relations | 1 | 2019 | 101 | 0.160 |
Why?
|
Erythema Infectiosum | 1 | 2018 | 15 | 0.160 |
Why?
|
Models, Biological | 2 | 2016 | 9583 | 0.160 |
Why?
|
Coronavirus Infections | 3 | 2020 | 3133 | 0.160 |
Why?
|
Dendritic Cells | 2 | 2020 | 2725 | 0.150 |
Why?
|
Pneumonia, Viral | 3 | 2020 | 3240 | 0.150 |
Why?
|
Postnatal Care | 1 | 2019 | 236 | 0.150 |
Why?
|
Africa South of the Sahara | 4 | 2020 | 724 | 0.150 |
Why?
|
RNA, Viral | 4 | 2016 | 2902 | 0.150 |
Why?
|
Benzoxazines | 1 | 2019 | 301 | 0.150 |
Why?
|
New York City | 1 | 2019 | 710 | 0.150 |
Why?
|
Viremia | 2 | 2018 | 736 | 0.150 |
Why?
|
Counseling | 2 | 2020 | 1523 | 0.140 |
Why?
|
Anemia, Hemolytic, Autoimmune | 1 | 2018 | 142 | 0.140 |
Why?
|
Child Health Services | 1 | 2020 | 667 | 0.120 |
Why?
|
Policy Making | 1 | 2018 | 554 | 0.120 |
Why?
|
Cote d'Ivoire | 4 | 2016 | 56 | 0.120 |
Why?
|
HIV Integrase Inhibitors | 1 | 2016 | 142 | 0.120 |
Why?
|
Homosexuality, Male | 1 | 2021 | 1240 | 0.120 |
Why?
|
Virus Replication | 2 | 2020 | 2534 | 0.110 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2017 | 602 | 0.110 |
Why?
|
HIV-2 | 1 | 2013 | 167 | 0.110 |
Why?
|
Survival Analysis | 2 | 2019 | 10252 | 0.110 |
Why?
|
Oxazines | 3 | 2019 | 298 | 0.110 |
Why?
|
Prenatal Care | 1 | 2019 | 1092 | 0.110 |
Why?
|
Cohort Studies | 8 | 2020 | 40561 | 0.100 |
Why?
|
Outpatients | 1 | 2019 | 1486 | 0.100 |
Why?
|
Vascular Surgical Procedures | 1 | 2020 | 1475 | 0.100 |
Why?
|
Silicones | 1 | 2012 | 250 | 0.100 |
Why?
|
Africa, Southern | 2 | 2020 | 57 | 0.090 |
Why?
|
Central America | 2 | 2020 | 68 | 0.090 |
Why?
|
Family Planning Services | 1 | 2013 | 263 | 0.090 |
Why?
|
AIDS-Related Opportunistic Infections | 1 | 2014 | 657 | 0.090 |
Why?
|
South America | 2 | 2020 | 181 | 0.090 |
Why?
|
Medication Adherence | 3 | 2020 | 2063 | 0.090 |
Why?
|
Caribbean Region | 2 | 2020 | 194 | 0.090 |
Why?
|
Quality Assurance, Health Care | 1 | 2020 | 2212 | 0.090 |
Why?
|
Clinical Trials, Phase IV as Topic | 1 | 2009 | 27 | 0.090 |
Why?
|
Pyridones | 3 | 2019 | 712 | 0.090 |
Why?
|
Developing Countries | 3 | 2011 | 2815 | 0.080 |
Why?
|
Consent Forms | 1 | 2009 | 53 | 0.080 |
Why?
|
Bottle Feeding | 1 | 2008 | 66 | 0.080 |
Why?
|
Health Facilities | 1 | 2014 | 573 | 0.080 |
Why?
|
Anemia | 1 | 2018 | 1506 | 0.080 |
Why?
|
Drug Resistance, Viral | 1 | 2013 | 820 | 0.080 |
Why?
|
Polymerase Chain Reaction | 1 | 2017 | 6171 | 0.080 |
Why?
|
Incidence | 5 | 2020 | 20947 | 0.080 |
Why?
|
National Health Programs | 1 | 2011 | 445 | 0.080 |
Why?
|
Health Services | 1 | 2013 | 758 | 0.070 |
Why?
|
United States | 5 | 2021 | 69872 | 0.070 |
Why?
|
Critical Care | 1 | 2020 | 2647 | 0.070 |
Why?
|
Treatment Outcome | 5 | 2019 | 63114 | 0.070 |
Why?
|
Brachial Artery | 1 | 2008 | 369 | 0.070 |
Why?
|
Developed Countries | 1 | 2009 | 437 | 0.070 |
Why?
|
Pandemics | 3 | 2020 | 8388 | 0.070 |
Why?
|
Models, Statistical | 2 | 2017 | 5102 | 0.070 |
Why?
|
Arm | 1 | 2008 | 589 | 0.060 |
Why?
|
Arteriovenous Shunt, Surgical | 1 | 2008 | 277 | 0.060 |
Why?
|
Sensitivity and Specificity | 1 | 2020 | 14722 | 0.060 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2009 | 841 | 0.060 |
Why?
|
Social Work | 1 | 2006 | 162 | 0.060 |
Why?
|
Drug Monitoring | 1 | 2010 | 956 | 0.060 |
Why?
|
Retrospective Studies | 9 | 2020 | 77449 | 0.060 |
Why?
|
Piperazines | 3 | 2019 | 2488 | 0.060 |
Why?
|
Blood Vessel Prosthesis | 1 | 2008 | 933 | 0.060 |
Why?
|
Device Removal | 1 | 2008 | 656 | 0.060 |
Why?
|
Clinical Protocols | 1 | 2009 | 1462 | 0.050 |
Why?
|
Software | 1 | 2017 | 4443 | 0.050 |
Why?
|
Prosthesis-Related Infections | 1 | 2008 | 538 | 0.050 |
Why?
|
California | 1 | 2006 | 1402 | 0.050 |
Why?
|
Patient Care Team | 2 | 2020 | 2531 | 0.050 |
Why?
|
Aging | 1 | 2020 | 8664 | 0.050 |
Why?
|
Africa, Central | 1 | 2020 | 7 | 0.050 |
Why?
|
Asia, Southeastern | 1 | 2020 | 111 | 0.050 |
Why?
|
Time Factors | 3 | 2018 | 40075 | 0.050 |
Why?
|
Pneumonia | 1 | 2012 | 2133 | 0.040 |
Why?
|
Culicidae | 1 | 2020 | 105 | 0.040 |
Why?
|
Pediatrics | 2 | 2012 | 3475 | 0.040 |
Why?
|
Organizational Case Studies | 1 | 2020 | 299 | 0.040 |
Why?
|
Asymptomatic Infections | 1 | 2020 | 128 | 0.040 |
Why?
|
Clinical Trials as Topic | 1 | 2015 | 7913 | 0.040 |
Why?
|
Malawi | 1 | 2020 | 282 | 0.040 |
Why?
|
Asia | 1 | 2020 | 610 | 0.040 |
Why?
|
Fertilization | 1 | 2020 | 196 | 0.040 |
Why?
|
Hydrocortisone | 1 | 2006 | 1826 | 0.040 |
Why?
|
Risk Factors | 4 | 2018 | 72290 | 0.040 |
Why?
|
Mozambique | 1 | 2018 | 54 | 0.040 |
Why?
|
Blood Vessel Prosthesis Implantation | 1 | 2008 | 1390 | 0.040 |
Why?
|
Alkynes | 1 | 2019 | 306 | 0.040 |
Why?
|
Parvovirus B19, Human | 1 | 2018 | 38 | 0.040 |
Why?
|
Nucleic Acid Amplification Techniques | 1 | 2020 | 323 | 0.040 |
Why?
|
Serologic Tests | 1 | 2020 | 374 | 0.040 |
Why?
|
Cyclopropanes | 1 | 2019 | 416 | 0.040 |
Why?
|
Program Evaluation | 1 | 2006 | 2488 | 0.040 |
Why?
|
Boston | 2 | 2020 | 9313 | 0.040 |
Why?
|
Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2017 | 109 | 0.040 |
Why?
|
Treatment Failure | 2 | 2013 | 2618 | 0.040 |
Why?
|
Middle Aged | 7 | 2019 | 213383 | 0.030 |
Why?
|
Lost to Follow-Up | 1 | 2016 | 105 | 0.030 |
Why?
|
Botswana | 1 | 2019 | 1040 | 0.030 |
Why?
|
Fetal Death | 1 | 2018 | 448 | 0.030 |
Why?
|
Child, Orphaned | 1 | 2016 | 55 | 0.030 |
Why?
|
Catheterization, Central Venous | 1 | 2020 | 514 | 0.030 |
Why?
|
Myeloid Cells | 1 | 2020 | 810 | 0.030 |
Why?
|
Pregnant Women | 1 | 2020 | 568 | 0.030 |
Why?
|
Multicenter Studies as Topic | 1 | 2020 | 1677 | 0.030 |
Why?
|
Monte Carlo Method | 1 | 2020 | 1254 | 0.030 |
Why?
|
China | 1 | 2020 | 2248 | 0.030 |
Why?
|
Age Distribution | 1 | 2020 | 2902 | 0.030 |
Why?
|
HIV Protease Inhibitors | 1 | 2016 | 430 | 0.030 |
Why?
|
Pregnancy Trimester, Third | 1 | 2016 | 571 | 0.030 |
Why?
|
Africa, Western | 1 | 2013 | 154 | 0.030 |
Why?
|
Lung | 1 | 2012 | 9856 | 0.030 |
Why?
|
Leukocytes, Mononuclear | 1 | 2020 | 1836 | 0.030 |
Why?
|
Pregnancy Trimester, Second | 1 | 2016 | 732 | 0.030 |
Why?
|
Cells, Cultured | 2 | 2020 | 19229 | 0.030 |
Why?
|
Infection Control | 1 | 2020 | 966 | 0.030 |
Why?
|
Immunocompromised Host | 1 | 2018 | 847 | 0.030 |
Why?
|
Reverse Transcriptase Inhibitors | 1 | 2016 | 615 | 0.030 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2020 | 9959 | 0.030 |
Why?
|
Drug Administration Schedule | 1 | 2020 | 4933 | 0.030 |
Why?
|
Prevalence | 2 | 2020 | 15226 | 0.030 |
Why?
|
Cardiovascular Diseases | 1 | 2017 | 15165 | 0.030 |
Why?
|
Follow-Up Studies | 3 | 2017 | 39050 | 0.020 |
Why?
|
Killer Cells, Natural | 1 | 2020 | 2133 | 0.020 |
Why?
|
Drug Substitution | 1 | 2013 | 281 | 0.020 |
Why?
|
Cross-Sectional Studies | 2 | 2016 | 25043 | 0.020 |
Why?
|
Adolescent Behavior | 1 | 2019 | 1151 | 0.020 |
Why?
|
Interpersonal Relations | 1 | 2018 | 1425 | 0.020 |
Why?
|
Monocytes | 1 | 2020 | 2596 | 0.020 |
Why?
|
Injections, Subcutaneous | 1 | 2012 | 666 | 0.020 |
Why?
|
Fever | 1 | 2018 | 1616 | 0.020 |
Why?
|
Headache | 1 | 2018 | 1226 | 0.020 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2017 | 1660 | 0.020 |
Why?
|
Academic Medical Centers | 1 | 2020 | 2759 | 0.020 |
Why?
|
Self Report | 1 | 2020 | 3558 | 0.020 |
Why?
|
Transsexualism | 1 | 2012 | 178 | 0.020 |
Why?
|
Cough | 1 | 2012 | 555 | 0.020 |
Why?
|
Genotype | 2 | 2013 | 12951 | 0.020 |
Why?
|
Immunity, Innate | 1 | 2020 | 2958 | 0.020 |
Why?
|
Rural Population | 1 | 2018 | 2210 | 0.020 |
Why?
|
Ligation | 1 | 2008 | 453 | 0.020 |
Why?
|
Hospitalization | 2 | 2020 | 10262 | 0.020 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2020 | 4386 | 0.020 |
Why?
|
Microbial Sensitivity Tests | 1 | 2013 | 1877 | 0.020 |
Why?
|
Gestational Age | 1 | 2016 | 3493 | 0.020 |
Why?
|
B-Lymphocytes | 1 | 2020 | 4665 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2020 | 4479 | 0.020 |
Why?
|
Health Personnel | 1 | 2020 | 3218 | 0.020 |
Why?
|
Transcription, Genetic | 1 | 2020 | 7722 | 0.020 |
Why?
|
Patient Compliance | 1 | 2016 | 2684 | 0.020 |
Why?
|
Morbidity | 1 | 2011 | 1769 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2016 | 6489 | 0.020 |
Why?
|
Proto-Oncogene Proteins | 1 | 2017 | 4554 | 0.020 |
Why?
|
Pregnancy Complications | 1 | 2019 | 2861 | 0.020 |
Why?
|
Prospective Studies | 3 | 2016 | 53288 | 0.020 |
Why?
|
Crohn Disease | 1 | 2018 | 2303 | 0.020 |
Why?
|
Databases, Factual | 1 | 2020 | 7729 | 0.020 |
Why?
|
Dyspnea | 1 | 2012 | 1303 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2020 | 9438 | 0.010 |
Why?
|
Cell Line | 1 | 2017 | 15997 | 0.010 |
Why?
|
Quality Improvement | 1 | 2018 | 3749 | 0.010 |
Why?
|
Disease Management | 1 | 2013 | 2459 | 0.010 |
Why?
|
Telemedicine | 1 | 2020 | 2872 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2018 | 12959 | 0.010 |
Why?
|
Survival Rate | 1 | 2016 | 12788 | 0.010 |
Why?
|
Research Design | 1 | 2018 | 5987 | 0.010 |
Why?
|
Ambulatory Care | 1 | 2013 | 2708 | 0.010 |
Why?
|
Smoking | 1 | 2017 | 8987 | 0.010 |
Why?
|
Mortality | 1 | 2011 | 2864 | 0.010 |
Why?
|
Renal Dialysis | 1 | 2008 | 1786 | 0.010 |
Why?
|
Aged | 3 | 2017 | 163280 | 0.010 |
Why?
|
Risk Assessment | 1 | 2019 | 23338 | 0.010 |
Why?
|
Kidney Failure, Chronic | 1 | 2008 | 2538 | 0.010 |
Why?
|
Disease Progression | 1 | 2012 | 13284 | 0.010 |
Why?
|
Registries | 1 | 2008 | 8089 | 0.010 |
Why?
|
Animals | 1 | 2020 | 168757 | 0.000 |
Why?
|